Metabolic / Weight Management
Mazdutide
Mazdutide is a dual-incretin therapeutic designed to manage obesity and type 2 diabetes by simultaneously modulating metabolic intake and energy expenditure.
Evidence: 0 articles
Goals: 0
Mechanism of Action
Mazdutide functions as a dual agonist that activates both the GLP-1 receptor and the glucagon receptor. By mimicking GLP-1, it enhances glucose-dependent insulin secretion and promotes satiety. Simultaneously, its glucagon receptor agonism is hypothesized to increase energy expenditure and lipid metabolism, potentially counteracting the glycemic effects of glucagon while leveraging its weight-loss benefits.
Evidence Level
Clinical Trial - Human
0 studies published
Pharmacology
Molecular Weight
4476 Da